Linezolid: The first antibiotic from the class of oxazolidinones;Linezolid: Das erste antibiotikum aus der klasse der Zoxazolidinone

Chemotherapie Journal

Volumn 11, Issue 1, 2002, Pages 1-11

  Halle, Elke ^a   Majcher Peszynska, Jolanta ^a   Drewelow, Bernd ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFPODOXIME; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; DICLOXACILLIN; LINEZOLID; OXACILLIN; OXAZOLIDINONE DERIVATIVE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG METABOLISM; ENTEROCOCCUS FAECALIS; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STREPTOCOCCUS PNEUMONIAE;

EID: 0036176403     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Methicillin-resistant staphylococcus aureus infection in a renal allograft recipient treated successfully with a novel new antimicrobial agent (linezolid): New treatment options for infections due to resistant organisms
2. Outcomes with linezolid from an ongoing compassionate use trial of patients with significant, resistent, gram-positive infections
3. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections
4. Pharmacokinetics of linezolid in subjects with varying degrees of renal function and on dialysis
5. In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones
6. Efficacy of linezolid in skin and soft tissue infections
7. Nosocomial enterococci resistant to vancomycin - United States: 1988-93
8. Staphylococcus aureus with reduced susceptibilty to vancomycin - United States
9. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections
10. Population pharmacodynamic assessment of linezolid efficacy in community-acquired pneumonia (CAP), skin and soft tissue (SST) infections and bacteremia (BAC)
11. The development of a population pharmacokinetic (PK) model for linezolid
12. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model
13. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
14. Comparative in-vitro activitites of moxifloxacin, trovafloxacin, quinupristin/Tagalfopristin and linezolid against staphylococci
15. Pharmacostatistical modelling of hematologic effects of linezolid in seriously ill patients
16. Emergence of heterogenous intermediate vancomycin resistance in Staphylococcus aureus in the Düsseldorf area
17. Chinolonresistenz in der klinischen praxis
18. Susceptibility testing of linezolid by two standard methods
19. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
20. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, and non-quinolones linezolid, quinupristin-dalfopristin, gentamicin and vancomycin against clinical isolates of ciprofloxacin-resistant and -suceptible Staphylococcus aureus strains
21. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones
22. In vitro activities of two oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulasenegative Staphylococcus species
23. In vitro activities of oxazolidinone compounds U 199592 and U 100766 against Staphylococcus aureus and Staphylococcus epidermidis
24. Historical yearly usage of vancomycin
25. Resistenzentwicklung bei staphylokokken und anderen grampositiven erregern gegenüber chemotherapeutika im mitteleuropäischen raum
26. Resistenzsituation bei klinisch wichtigen infektionserregern gegenüber chemotherapeutika in mitteleuropa
27. The oxazolidinone eperezolid binds to the 5OS ribosomal subunit and competes with binding of chloramphenicol and lincomycin
28. Isolation of a vancomycin-resistant enterococcal strain with reduced susceptibility to linezolid
29. In vitro activities of two novel oxazolidinones (U 100592 and U 100766) a new fluorquinolone (trovafloxacin), and dalfopristin/quinupristin against Stapylococcus aureus and Staphylococcus epidermidis
30. In vitro activities of oxazolidinones U-100592 and U 1007666 against penicillin-resistant and cephalosporin-resistant strains of Streptococus pneumoniae
31. Successful treatment of vancomycin-resistant enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin)
32. Linezolid - First of a new class of antibiotics. 8
33. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
34. Successful treatment of persistent vancomycin-resistant enterococcus faecium bacteremia with linezolid and gentamicin
35. Population pharmacodynamics of linezolid in seriously ill adult patients from a compassionate use protokol
36. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System
37. Oxazolidinones, a new class of synthetic antibacterial agents: In vitro and in vivo activities of DuP 105 and DuP 721
38. A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam
39. Activities of RPR 106972 (a new oral streptogramin), ceftidoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U 100766) and other oral and parenteral agents against 203 Penicillin-susceptible and -resistant pneumococci
40. Linezolid safety, tolerance and pharmacocinetics following oral dosing twice daily for 14,5 days
41. Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections
42. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
43. Survey of susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to 26 antimicrobial agents: A prospective USA study
44. In vitro metabolism of linezolid: Lack of induction or inhibition of cytochrome P 450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586
45. The in-vitro activity of linezolid (U-100766) and tentative breakpoints
46. Safety and tolerance of linezolid in phase II trial
47. In vitro activity of linezolid and eperozolid against anaerobic bacteria
48. Development of linezolid-resistent Enterococcus faecium in two compassionate use program patients treated with linezolid
49. In vitro activities of U-100592 and U100766, novel oxazolidinone antibacterial agents